Drug company GlaxoSmithKline PLC said it has withdrawn an application to the European Medicines Agency related to its ovarian-cancer treatment Votrient after analyzing data from a Phase III study.
from WSJ.com: US Business http://ift.tt/1iRAjL0
via IFTTT
from WSJ.com: US Business http://ift.tt/1iRAjL0
via IFTTT
No comments:
Post a Comment